JP2025507820A - キノリンcGasアンタゴニスト化合物 - Google Patents

キノリンcGasアンタゴニスト化合物 Download PDF

Info

Publication number
JP2025507820A
JP2025507820A JP2024551891A JP2024551891A JP2025507820A JP 2025507820 A JP2025507820 A JP 2025507820A JP 2024551891 A JP2024551891 A JP 2024551891A JP 2024551891 A JP2024551891 A JP 2024551891A JP 2025507820 A JP2025507820 A JP 2025507820A
Authority
JP
Japan
Prior art keywords
alkyl
ring
compound
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551891A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023168367A5 (https=
JP2025507820A5 (https=
Inventor
ウェイ、チー
シー、へピン
ツーチャンツ、マット
チウ、ジエン
ウー、ユートン
タン、フイリン
サン、リジュン
チェン、チュオ
チェン、ジージエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2025507820A publication Critical patent/JP2025507820A/ja
Publication of JPWO2023168367A5 publication Critical patent/JPWO2023168367A5/ja
Publication of JP2025507820A5 publication Critical patent/JP2025507820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024551891A 2022-03-02 2023-03-02 キノリンcGasアンタゴニスト化合物 Pending JP2025507820A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315968P 2022-03-02 2022-03-02
US63/315,968 2022-03-02
US202363478467P 2023-01-04 2023-01-04
US63/478,467 2023-01-04
PCT/US2023/063623 WO2023168367A1 (en) 2022-03-02 2023-03-02 QUINOLINE cGAS ANTAGONIST COMPOUNDS

Publications (3)

Publication Number Publication Date
JP2025507820A true JP2025507820A (ja) 2025-03-21
JPWO2023168367A5 JPWO2023168367A5 (https=) 2026-03-10
JP2025507820A5 JP2025507820A5 (https=) 2026-03-10

Family

ID=85781707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551891A Pending JP2025507820A (ja) 2022-03-02 2023-03-02 キノリンcGasアンタゴニスト化合物

Country Status (11)

Country Link
US (3) US12281078B2 (https=)
EP (1) EP4486734A1 (https=)
JP (1) JP2025507820A (https=)
KR (1) KR20250004639A (https=)
CN (1) CN119137112A (https=)
AU (1) AU2023228915A1 (https=)
CA (1) CA3253386A1 (https=)
IL (1) IL315346A (https=)
MX (1) MX2024010674A (https=)
TW (1) TW202342021A (https=)
WO (1) WO2023168367A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
CN119137112A (zh) 2022-03-02 2024-12-13 免疫传感器治疗股份有限公司 喹啉cGAS拮抗剂化合物
WO2026050765A1 (en) 2024-08-30 2026-03-05 Immunesensor Therapeutics, Inc. Solid forms and salts of a quinoline cgas antagonist compound
WO2026057087A1 (zh) * 2024-09-14 2026-03-19 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) * 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
AU2008303602A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
JP2019501904A (ja) * 2015-12-14 2019-01-24 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada Dnaメチルトランスフェラーゼの阻害剤としての2,4,6,7−四置換キノリン化合物
CN109111426B (zh) 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物,及其用途
IL302338B2 (en) 2017-09-08 2024-10-01 Univ Leland Stanford Junior Enpp1 inhibitors and their use for the treatment of cancer
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
US12064433B2 (en) 2018-07-27 2024-08-20 Arcus Biosciences, Inc. Pyridone A2R antagonists
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020142735A1 (en) 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN115209883B (zh) 2020-01-20 2025-05-20 新月生物科学 新型细胞代谢调节化合物及其用途
JP2023532998A (ja) 2020-07-06 2023-08-01 クレセンタ バイオサイエンシズ 新規細胞代謝調節化合物およびそのウイルス性疾患の治療のための使用
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
CN119137112A (zh) 2022-03-02 2024-12-13 免疫传感器治疗股份有限公司 喹啉cGAS拮抗剂化合物

Also Published As

Publication number Publication date
AU2023228915A1 (en) 2024-09-19
US20240002346A1 (en) 2024-01-04
US20230357158A1 (en) 2023-11-09
TW202342021A (zh) 2023-11-01
CN119137112A (zh) 2024-12-13
KR20250004639A (ko) 2025-01-08
CA3253386A1 (en) 2023-09-07
US12091387B2 (en) 2024-09-17
MX2024010674A (es) 2024-11-08
EP4486734A1 (en) 2025-01-08
IL315346A (en) 2024-11-01
US12281078B2 (en) 2025-04-22
US20260042737A1 (en) 2026-02-12
WO2023168367A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
US11267800B2 (en) Cyclohexyl acid triazole azines as LPA antagonists
JP2025507820A (ja) キノリンcGasアンタゴニスト化合物
KR20230062845A (ko) 퀴놀린 cgas 길항제 화합물
KR102516038B1 (ko) cGAS 길항제 화합물
JP6663857B2 (ja) ピラゾロピリジンおよびピラゾロピリミジン
AU2019416589A1 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
KR20200065024A (ko) 화학적 화합물
CA2930414A1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
KR20200088518A (ko) 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
CA2899646A1 (en) Substituted xanthines and methods of use thereof
EA029892B1 (ru) Азотсодержащее гетероциклическое соединение
JP7777596B2 (ja) Cd38阻害剤としてのキノリン及びアザキノリン
EP4423068B1 (en) Rxfp1 agonists
JPWO2023168367A5 (https=)
HK40120448A (zh) 喹啉cgas拮抗剂化合物
HK40094674A (zh) 喹啉cgas拮抗剂化合物
CN121159573A (zh) Cbl-b调节剂制备方法和用途
HK40066535B (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
HK40066535A (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
HK40004439B (zh) Cgas拮抗剂化合物
HK1234392A1 (en) Pyrazolopyridines and pyrazolopyrimidines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260302